CN104825479A - 淫羊藿次苷类化合物、其制备方法,及其在促进人细胞产生γ-干扰素作用和在疾病治疗中的应用 - Google Patents
淫羊藿次苷类化合物、其制备方法,及其在促进人细胞产生γ-干扰素作用和在疾病治疗中的应用 Download PDFInfo
- Publication number
- CN104825479A CN104825479A CN201510264195.5A CN201510264195A CN104825479A CN 104825479 A CN104825479 A CN 104825479A CN 201510264195 A CN201510264195 A CN 201510264195A CN 104825479 A CN104825479 A CN 104825479A
- Authority
- CN
- China
- Prior art keywords
- icariside
- och
- compounds
- formula
- epimedroside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010074328 Interferon-gamma Proteins 0.000 title claims abstract description 59
- 102000008070 Interferon-gamma Human genes 0.000 title claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 13
- 201000010099 disease Diseases 0.000 title claims abstract description 12
- 229960003130 interferon gamma Drugs 0.000 title claims abstract description 5
- 230000001737 promoting effect Effects 0.000 title claims abstract description 4
- IYCPMVXIUPYNHI-UHFFFAOYSA-N Icariside I Natural products C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-UHFFFAOYSA-N 0.000 title claims description 107
- 229930182721 icariside Natural products 0.000 title claims description 33
- 238000002360 preparation method Methods 0.000 title claims description 21
- 210000005260 human cell Anatomy 0.000 title abstract 2
- 241000282414 Homo sapiens Species 0.000 claims abstract description 54
- 239000003814 drug Substances 0.000 claims abstract description 45
- 210000004027 cell Anatomy 0.000 claims abstract description 37
- 230000036039 immunity Effects 0.000 claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 4
- 229930014626 natural product Natural products 0.000 claims abstract description 4
- 208000005176 Hepatitis C Diseases 0.000 claims abstract description 3
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 3
- 206010022000 influenza Diseases 0.000 claims abstract description 3
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims abstract description 3
- IYCPMVXIUPYNHI-WPKKLUCLSA-N 3,5-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-WPKKLUCLSA-N 0.000 claims description 74
- 150000001875 compounds Chemical class 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 49
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 41
- 102100037850 Interferon gamma Human genes 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 229940044627 gamma-interferon Drugs 0.000 claims description 20
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 claims description 19
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims description 19
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims description 19
- OGYXOOJUJQIDOX-FVCAYHPDSA-N 5-hydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=C(CC=C(C)C)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC(O)=C2C1=O OGYXOOJUJQIDOX-FVCAYHPDSA-N 0.000 claims description 15
- OGYXOOJUJQIDOX-UHFFFAOYSA-N epimedoside A Natural products OC1C(O)C(O)C(C)OC1OC1=C(C=2C=CC(O)=CC=2)OC2=C(CC=C(C)C)C(OC3C(C(O)C(O)C(CO)O3)O)=CC(O)=C2C1=O OGYXOOJUJQIDOX-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- -1 Cyclohexylamino Chemical group 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 9
- 210000005259 peripheral blood Anatomy 0.000 claims description 9
- 239000011886 peripheral blood Substances 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- 230000000638 stimulation Effects 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 8
- 230000002255 enzymatic effect Effects 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 4
- 102000015636 Oligopeptides Human genes 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000008265 rhamnosides Chemical class 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 238000001212 derivatisation Methods 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000006911 enzymatic reaction Methods 0.000 claims 2
- 230000003796 beauty Effects 0.000 claims 1
- 239000008366 buffered solution Substances 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000009169 immunotherapy Methods 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241001362421 Epimedium brevicornu Species 0.000 abstract 1
- 238000007385 chemical modification Methods 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 239000000047 product Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 17
- 210000004698 lymphocyte Anatomy 0.000 description 14
- 230000008569 process Effects 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 201000008827 tuberculosis Diseases 0.000 description 11
- 238000000926 separation method Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 9
- 238000012797 qualification Methods 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000011580 nude mouse model Methods 0.000 description 8
- 230000007923 virulence factor Effects 0.000 description 8
- 239000000304 virulence factor Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 229930182470 glycoside Natural products 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 150000002338 glycosides Chemical class 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002151 Pleural effusion Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- HWBLTYHIEYOAOL-UHFFFAOYSA-N Diisopropyl sulfate Chemical compound CC(C)OS(=O)(=O)OC(C)C HWBLTYHIEYOAOL-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 101710179016 Protein gamma Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
Abstract
Description
Claims (15)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810234861.4A CN108486196A (zh) | 2015-05-20 | 2015-05-20 | 一种淫羊藿次苷i或淫羊藿次苷c的制备方法 |
CN201810235323.7A CN108299530B (zh) | 2015-05-20 | 2015-05-20 | 一种淫羊藿次苷类化合物及其制备方法和用途 |
CN201510264195.5A CN104825479B (zh) | 2015-05-20 | 2015-05-20 | 淫羊藿次苷类化合物、其制备方法,及其在促进人细胞产生γ-干扰素作用和在疾病治疗中的应用 |
US15/745,784 US20180201639A1 (en) | 2015-05-20 | 2015-06-29 | Icariside compound, preparation method thereof, and application thereof |
PCT/CN2015/082591 WO2016183905A1 (zh) | 2015-05-20 | 2015-06-29 | 淫羊藿次苷类化合物,其制备方法,及其在促进人细胞产生γ-干扰素作用和在疾病治疗中的应用 |
GB1721295.2A GB2557741B (en) | 2015-05-20 | 2015-06-29 | Icariside compound, preperation method thereof, and application thereof |
US16/444,367 US11117919B2 (en) | 2015-05-20 | 2019-06-18 | Icariside compound, preparation method thereof, and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510264195.5A CN104825479B (zh) | 2015-05-20 | 2015-05-20 | 淫羊藿次苷类化合物、其制备方法,及其在促进人细胞产生γ-干扰素作用和在疾病治疗中的应用 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810235323.7A Division CN108299530B (zh) | 2015-05-20 | 2015-05-20 | 一种淫羊藿次苷类化合物及其制备方法和用途 |
CN201810234861.4A Division CN108486196A (zh) | 2015-05-20 | 2015-05-20 | 一种淫羊藿次苷i或淫羊藿次苷c的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104825479A true CN104825479A (zh) | 2015-08-12 |
CN104825479B CN104825479B (zh) | 2018-06-05 |
Family
ID=53803936
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810234861.4A Pending CN108486196A (zh) | 2015-05-20 | 2015-05-20 | 一种淫羊藿次苷i或淫羊藿次苷c的制备方法 |
CN201810235323.7A Active CN108299530B (zh) | 2015-05-20 | 2015-05-20 | 一种淫羊藿次苷类化合物及其制备方法和用途 |
CN201510264195.5A Active CN104825479B (zh) | 2015-05-20 | 2015-05-20 | 淫羊藿次苷类化合物、其制备方法,及其在促进人细胞产生γ-干扰素作用和在疾病治疗中的应用 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810234861.4A Pending CN108486196A (zh) | 2015-05-20 | 2015-05-20 | 一种淫羊藿次苷i或淫羊藿次苷c的制备方法 |
CN201810235323.7A Active CN108299530B (zh) | 2015-05-20 | 2015-05-20 | 一种淫羊藿次苷类化合物及其制备方法和用途 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20180201639A1 (zh) |
CN (3) | CN108486196A (zh) |
GB (1) | GB2557741B (zh) |
WO (1) | WO2016183905A1 (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107669695A (zh) * | 2017-11-16 | 2018-02-09 | 遵义医学院 | 淫羊藿次苷ⅱ在制备抗乙型肝炎病毒产品中的应用 |
CN109265502A (zh) * | 2018-10-29 | 2019-01-25 | 广东金骏康生物技术有限公司 | 异戊二烯基黄酮化合物、衍生物、药物组合物及其应用 |
CN109320570A (zh) * | 2018-10-29 | 2019-02-12 | 广东金骏康生物技术有限公司 | 一种淫羊藿次苷ⅰ类化合物、衍生物、可药用盐及应用 |
CN109369747A (zh) * | 2018-10-29 | 2019-02-22 | 广东金骏康生物技术有限公司 | 淫羊藿次苷ⅰ化合物及其衍生物、药物组合物及其制备方法和应用 |
CN109369748A (zh) * | 2018-10-29 | 2019-02-22 | 广东金骏康生物技术有限公司 | 一种淫羊藿次苷ⅰ类化合物、衍生物、药物组合物及其应用 |
CN109364088A (zh) * | 2018-10-29 | 2019-02-22 | 广东金骏康生物技术有限公司 | 一种淫羊藿次苷i类化合物用于制备ido抑制剂的用途 |
CN111228287A (zh) * | 2020-04-15 | 2020-06-05 | 广东金骏康生物技术有限公司 | 淫羊藿黄酮苷类化合物在制备治疗黑色素瘤的药物中的应用 |
CN111700900A (zh) * | 2020-05-15 | 2020-09-25 | 广东金骏康生物技术有限公司 | 一种天然免疫活化剂、til细胞促进剂及其应用 |
CN113136378A (zh) * | 2021-06-22 | 2021-07-20 | 广东金骏康生物技术有限公司 | 一种鼠李糖苷酶TpeRha突变体及其制备方法和应用 |
CN113249357A (zh) * | 2021-06-22 | 2021-08-13 | 广东金骏康生物技术有限公司 | 一种鼠李糖苷酶TpeRha-H570A突变体及其制备方法和应用 |
CN113512542A (zh) * | 2021-06-22 | 2021-10-19 | 广东金骏康生物技术有限公司 | 一种鼠李糖苷酶突变体及其制备方法和应用 |
CN114410734A (zh) * | 2021-12-07 | 2022-04-29 | 广东工业大学 | 淫羊藿次苷ⅰ或根皮素在制备核酸胞嘧啶脱氨酶apobec3b抑制剂中的应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110684003A (zh) * | 2019-09-30 | 2020-01-14 | 中国科学院成都生物研究所 | 一种简便高效的淫羊藿素及其衍生物的全合成方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101113157A (zh) * | 2006-07-28 | 2008-01-30 | 上海特化医药科技有限公司 | 异戊烯基黄酮衍生物、制备方法及其用途 |
CN101316573A (zh) * | 2005-11-30 | 2008-12-03 | 株式会社太平洋 | 一种含有淫羊藿苷的水解产物的化妆品组合物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399579B1 (en) * | 2000-08-15 | 2002-06-04 | Hauser, Inc. | Compositions comprising icariside I and anhydroicaritin and methods for making the same |
CA2471223A1 (en) * | 2001-12-21 | 2003-07-24 | Eastern Virginia Medical School | Method for analyzing effects of medical agents |
CN1969952A (zh) * | 2005-11-24 | 2007-05-30 | 北京奇源益德药物研究所 | 抗病毒中药制剂及其制备方法、质控方法和应用 |
CN100396313C (zh) * | 2005-12-15 | 2008-06-25 | 陈长安 | 治疗尘肺病的中草药制剂 |
CN101205223B (zh) * | 2006-12-18 | 2010-10-06 | 李毅林 | 一种天然产物淫羊藿苷类化合物的全合成方法 |
WO2008089669A1 (en) * | 2007-01-23 | 2008-07-31 | Tongjitang Chinese Medicines Company | A novel combination of epimedium-derived-flavonoids-fractions for prevention of steroid-induced osteonecrosis |
CN100500160C (zh) * | 2007-05-11 | 2009-06-17 | 澳美制药厂有限公司 | 含淫羊藿有效成分的药物组合物及其用途 |
CN101760487B (zh) * | 2009-08-18 | 2012-04-04 | 江苏省中医药研究院 | 一种淫羊藿苷元的制备方法 |
EP2483683A1 (en) * | 2009-09-28 | 2012-08-08 | TheraMab GmbH | Method for preclinical testing of immunomodulatory drugs |
US20130084601A1 (en) * | 2010-06-14 | 2013-04-04 | Amorepacific Corporation | Novel soil microorganism, novel oxidoreductase separated from the soil microorganism, gene encoding the oxidoreductase, and method for producing aglycones using the microorganism, the oxidoreductase and the gene |
CN102167690B (zh) * | 2011-03-14 | 2014-04-02 | 暨南大学 | 一种淫羊藿苷苷元衍生物及其制备方法和应用 |
CN104411309B (zh) * | 2013-04-24 | 2018-03-09 | 北京珅奥基医药科技有限公司 | 阿可拉定在制备用于治疗原发性肝癌的药物中的用途 |
CN104561178A (zh) * | 2014-06-19 | 2015-04-29 | 山东大学(威海) | 采用柚苷酶从淫羊藿苷获得淫羊藿苷元的方法 |
CN104547250A (zh) * | 2015-01-09 | 2015-04-29 | 郭良苏 | 一种抑制癌细胞扩散的中药组合物及其制备方法 |
CN104491752A (zh) * | 2015-01-12 | 2015-04-08 | 白忠可 | 慢性迁延性肝炎疏肝清热剂及制备方法 |
-
2015
- 2015-05-20 CN CN201810234861.4A patent/CN108486196A/zh active Pending
- 2015-05-20 CN CN201810235323.7A patent/CN108299530B/zh active Active
- 2015-05-20 CN CN201510264195.5A patent/CN104825479B/zh active Active
- 2015-06-29 WO PCT/CN2015/082591 patent/WO2016183905A1/zh active Application Filing
- 2015-06-29 GB GB1721295.2A patent/GB2557741B/en active Active
- 2015-06-29 US US15/745,784 patent/US20180201639A1/en not_active Abandoned
-
2019
- 2019-06-18 US US16/444,367 patent/US11117919B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101316573A (zh) * | 2005-11-30 | 2008-12-03 | 株式会社太平洋 | 一种含有淫羊藿苷的水解产物的化妆品组合物 |
CN101113157A (zh) * | 2006-07-28 | 2008-01-30 | 上海特化医药科技有限公司 | 异戊烯基黄酮衍生物、制备方法及其用途 |
Non-Patent Citations (1)
Title |
---|
孟宁 等: "淫羊藿属植物化学成分及药理活性研究进展", 《西北植物学报》 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107669695A (zh) * | 2017-11-16 | 2018-02-09 | 遵义医学院 | 淫羊藿次苷ⅱ在制备抗乙型肝炎病毒产品中的应用 |
CN107669695B (zh) * | 2017-11-16 | 2019-07-16 | 遵义医科大学 | 淫羊藿次苷ⅱ在制备抗乙型肝炎病毒产品中的应用 |
CN109265502A (zh) * | 2018-10-29 | 2019-01-25 | 广东金骏康生物技术有限公司 | 异戊二烯基黄酮化合物、衍生物、药物组合物及其应用 |
CN109320570A (zh) * | 2018-10-29 | 2019-02-12 | 广东金骏康生物技术有限公司 | 一种淫羊藿次苷ⅰ类化合物、衍生物、可药用盐及应用 |
CN109369747A (zh) * | 2018-10-29 | 2019-02-22 | 广东金骏康生物技术有限公司 | 淫羊藿次苷ⅰ化合物及其衍生物、药物组合物及其制备方法和应用 |
CN109369748A (zh) * | 2018-10-29 | 2019-02-22 | 广东金骏康生物技术有限公司 | 一种淫羊藿次苷ⅰ类化合物、衍生物、药物组合物及其应用 |
CN109364088A (zh) * | 2018-10-29 | 2019-02-22 | 广东金骏康生物技术有限公司 | 一种淫羊藿次苷i类化合物用于制备ido抑制剂的用途 |
CN111228287A (zh) * | 2020-04-15 | 2020-06-05 | 广东金骏康生物技术有限公司 | 淫羊藿黄酮苷类化合物在制备治疗黑色素瘤的药物中的应用 |
CN111700900A (zh) * | 2020-05-15 | 2020-09-25 | 广东金骏康生物技术有限公司 | 一种天然免疫活化剂、til细胞促进剂及其应用 |
CN113136378A (zh) * | 2021-06-22 | 2021-07-20 | 广东金骏康生物技术有限公司 | 一种鼠李糖苷酶TpeRha突变体及其制备方法和应用 |
CN113249357A (zh) * | 2021-06-22 | 2021-08-13 | 广东金骏康生物技术有限公司 | 一种鼠李糖苷酶TpeRha-H570A突变体及其制备方法和应用 |
CN113136378B (zh) * | 2021-06-22 | 2021-09-03 | 广东金骏康生物技术有限公司 | 一种鼠李糖苷酶TpeRha突变体及其制备方法和应用 |
CN113249357B (zh) * | 2021-06-22 | 2021-09-14 | 广东金骏康生物技术有限公司 | 一种鼠李糖苷酶TpeRha-H570A突变体及其制备方法和应用 |
CN113512542A (zh) * | 2021-06-22 | 2021-10-19 | 广东金骏康生物技术有限公司 | 一种鼠李糖苷酶突变体及其制备方法和应用 |
CN113512542B (zh) * | 2021-06-22 | 2021-11-23 | 广东金骏康生物技术有限公司 | 一种鼠李糖苷酶突变体及其制备方法和应用 |
CN114410734A (zh) * | 2021-12-07 | 2022-04-29 | 广东工业大学 | 淫羊藿次苷ⅰ或根皮素在制备核酸胞嘧啶脱氨酶apobec3b抑制剂中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108299530A (zh) | 2018-07-20 |
WO2016183905A1 (zh) | 2016-11-24 |
US20190300560A1 (en) | 2019-10-03 |
GB201721295D0 (en) | 2018-01-31 |
CN108486196A (zh) | 2018-09-04 |
GB2557741A (en) | 2018-06-27 |
CN108299530B (zh) | 2020-07-28 |
US11117919B2 (en) | 2021-09-14 |
CN104825479B (zh) | 2018-06-05 |
GB2557741B (en) | 2020-03-04 |
US20180201639A1 (en) | 2018-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104825479A (zh) | 淫羊藿次苷类化合物、其制备方法,及其在促进人细胞产生γ-干扰素作用和在疾病治疗中的应用 | |
Fan et al. | Effects of Astragalus polysaccharide liposome on lymphocyte proliferation in vitro and adjuvanticity in vivo | |
CN109320570A (zh) | 一种淫羊藿次苷ⅰ类化合物、衍生物、可药用盐及应用 | |
CN102212581A (zh) | 虫草多糖锗的生产制备方法及其应用 | |
CN101926844B (zh) | 瑞香狼毒提取物及其抗肿瘤作用 | |
CN106236796B (zh) | 一种小驳骨有效部位的制备方法及其应用 | |
CN101062041B (zh) | 葫芦素新的医药用途 | |
CN104208070B (zh) | 蒲公英甾醇在制备抗hbv的药物中的应用 | |
CN103142774B (zh) | 裂果薯总皂苷提取物在抗肝癌与鼻咽癌中的应用 | |
CN106008531A (zh) | 多环稠合大环内酰胺类化合物的抗胰腺癌用途 | |
CN108057049A (zh) | 一种增强细胞活力的中药组合物及其制备方法 | |
CN104706649A (zh) | 千层纸素苷在制备抗肿瘤药中的应用 | |
CN101824065B (zh) | 人参皂苷次级苷Rh1的脂肪酸单酯类化合物及制备方法 | |
Konusova et al. | Immunotropic effect of oyster mushroom beta-glucans, in combination with birch tree triterpene betulin, and beastim, dipeptide of gamma-D-glutamyl-tryptophan | |
CN102284018A (zh) | 一种牡蛎散整合型新剂型制备技术及其生产方法 | |
CN104744448B (zh) | 异黄酮化合物,其药物组合物及其制备方法和用途 | |
CN102232957B (zh) | 3-乙酰氧基-8,24-羊毛甾二烯-21-酸在制备预防、治疗肝癌或乳腺癌药物中的用途 | |
CN105663150B (zh) | 一种苯丙素类化合物及其药学上可接受的盐在制备治疗炎症性疾病的药物中的应用 | |
CN101502536B (zh) | 香柏总黄酮及其制备方法与医药用途 | |
CN104825499A (zh) | 舞茸提取物在制备抗抑郁症药物中的用途 | |
CN105878234B (zh) | 白术内酯ⅰ在制备增强免疫功能的药物及保健品中的应用 | |
CN105708845B (zh) | 一种苯丙素类化合物及其药学上可接受的盐在制备治疗炎症性疾病的药物中的应用 | |
CN107519216A (zh) | 红雪茶抗肿瘤活性部位及其制备方法与应用 | |
US11142530B2 (en) | Deep-sea fungus-derived anthraquinone compound and use thereof in preparing anti-allergic drugs | |
CN104083423A (zh) | 一种紫锥菊酊剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 528200 Room 210, 11 R&D workshops, No. 99 Taoyuan East Road, Shishan Town, Nanhai District, Foshan City, Guangdong Province (Residence Declaration) Patentee after: GOLDEN HEALTH BIOTECHNOLOGY Co.,Ltd. Address before: 528200 Block C, Nanhai Biomedical Technology Industry Center, Chinese Academy of Sciences, 181 Hongling Road, Shishan Town, Nanhai District, Foshan City, Guangdong Province Patentee before: FOSHAN GOLDEN HEALTH TECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Epimedium glycoside compounds, their preparation method, and their application in promoting human cell production of interferon gamma and in disease treatment Granted publication date: 20180605 Pledgee: Guangdong Nanhai rural commercial bank Limited by Share Ltd. Sanshui branch Pledgor: GOLDEN HEALTH BIOTECHNOLOGY Co.,Ltd. Registration number: Y2024980021094 |